CITATION REPORT List of articles citing

Combination therapy in hypertension

DOI: 10.1016/j.jash.2010.02.005 Journal of the American Society of Hypertension, 2010 , 4, 42-50.

Source: https://exaly.com/paper-pdf/49627432/citation-report.pdf

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
163	Fixed-dose combination and chronic kidney disease progression: which is the best?. 2010 , 19, 450-5		4
162	Rationale for triple-combination therapy for management of high blood pressure. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 869-78	2.3	54
161	IMPLICATION OF THE FIXED COMBINATIONS IN THE HYPERTENSION TREATMENT. <i>Rational Pharmacotherapy in Cardiology</i> , 2010 , 6, 550-557	0.5	
160	Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination?. 2010 , 8, 1609-18		5
159	Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine. 2010 , 26, 2263-76		5
158	Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. 2010 , 56, 824-30		141
157	Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. 2011 , 86, 444-56		84
156	Opinili de los mílicos expertos en hipertensili sobre las combinaciones triples en Espa li . Proyecto SINERGIA. 2011 , 28, 83-90		
155	Medical management of the patient with intermittent claudication. 2011 , 29, 363-79		10
154	Combination therapy as initial treatment for newly diagnosed hypertension. <i>American Heart Journal</i> , 2011 , 162, 340-6	4.9	38
153	Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. 2011 , 9, 9-19		5
152	Initial hypertension treatment: one combination fits most?. <i>Journal of the American Society of Hypertension</i> , 2011 , 5, 66-75		6
151	Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. <i>Journal of the American Society of Hypertension</i> , 2011 , 5, 417-24		6
150	Translation of hypertension treatment guidelines into practice: a review of implementation. Journal of the American Society of Hypertension, 2011 , 5, 197-207		41
149	Hypertension in diverse populations: a New York State Medicaid clinical guidance document. <i>Journal of the American Society of Hypertension</i> , 2011 , 5, 208-29		15
148	Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. 2011 , 7, 701-8		5
147	Bibliography. Pharmacology and therapeutics. Current world literature. 2011 , 20, 561-7		

146	Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?. 2011 , 20, 471-5		2
145	Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. 2011 , 16, 186-96		4
144	Angiotensin-converting enzyme inhibitors. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 667-75	2.3	70
143	Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products. <i>European Journal of Pharmaceutical Sciences</i> , 2011 , 44, 447-54	5.1	14
142	Mechanisms and management of hypertension in pregnant women. <i>Current Hypertension Reports</i> , 2011 , 13, 338-46	4.7	39
141	Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. 2011 , 123, 21-31		18
140	Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results. 2011 , 9, 421-7		2
139	Fixed-dose single tablet combinations: an alternative for initial therapy of patients with type 2 diabetes?. 2011 , 27, 2321-2		1
138	Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. 2012 , 35, 441-8		28
137	Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies. 2012 , 51 Suppl 4, iv27-33		9
137			9
	biologic therapies. 2012 , 51 Suppl 4, iv27-33	2.3	
136	biologic therapies. 2012, 51 Suppl 4, iv27-33 Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. 2012, 10, 293-303 Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.	2.3	4
136 135	biologic therapies. 2012, 51 Suppl 4, iv27-33 Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. 2012, 10, 293-303 Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. American Journal of Hypertension, 2012, 25, 379-88	2.3	4 21
136 135 134	Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. 2012, 10, 293-303 Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. American Journal of Hypertension, 2012, 25, 379-88 Evaluation and pharmacologic approach to patients with resistant hypertension. 2012, 124, 74-82	2.3	4 21 3
136 135 134	Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. 2012, 10, 293-303 Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. American Journal of Hypertension, 2012, 25, 379-88 Evaluation and pharmacologic approach to patients with resistant hypertension. 2012, 124, 74-82 Anti-obesity fixed-dose combinations. 2012, 12, 2-5 Hypertension in pregnancy: is it time for a new approach to treatment?. Journal of Hypertension,		4 21 3
136 135 134 133	Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. 2012, 10, 293-303 Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. American Journal of Hypertension, 2012, 25, 379-88 Evaluation and pharmacologic approach to patients with resistant hypertension. 2012, 124, 74-82 Anti-obesity fixed-dose combinations. 2012, 12, 2-5 Hypertension in pregnancy: is it time for a new approach to treatment?. Journal of Hypertension, 2012, 30, 1092-100 Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. Journal of Clinical Hypertension,	1.9	4 21 3 1 33

128 Combination Therapy in Hypertension Treatment. **2012**, 169-182

127	The Comparison between Listening to Al-Quran and Listening to Classical Music on the Brainwave Signal for the Alpha Band. 2012 ,		14
126	The Kidney in Heart Failure. 2012 ,		
125	Managing the Kidney when the Heart is Failing. 2012 ,		
124	Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial. 2012 , 53, 244-8		3
123	Should two-drug initial therapy for hypertension be recommended for all patients?. <i>Current Hypertension Reports</i> , 2012 , 14, 324-32	4.7	8
122	Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 149-57	2.3	16
121	Combination therapy for hypertension 2013: an update. <i>Journal of the American Society of Hypertension</i> , 2013 , 7, 401-7		14
120	Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. 2013 , 30, 549-60		7
119	Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 584-92	2.3	15
118	Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. 2013 , 13, 129-40		8
117	The treatment of hypertension during pregnancy: when should blood pressure medications be started?. 2013 , 15, 412		20
116	Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. 2013 , 11, 1115-24		6
115	Kidney Disease in Hypertension. 2013 , 270-279		
114	Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives. 2013 , 167, 2024-30		9
113	Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. 2013 , 62, 217-23		7
112	Management of hypertension with fixed-dose triple-combination treatments. 2013 , 7, 246-59		12
111	Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. 2013 , 61, 309-18		83

110	Combination antihypertensive therapy among patients with COPD. 2013 , 143, 1312-1320		13
109	Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. 2013 , 2013, 749830		4
108	Efficacy and tolerability of fixed dose combination of metoprolol and amlodipine in Indian patients with essential hypertension. 2013 , 4, 160-6		6
107	Commentary in support of a highly effective hypertension treatment algorithm. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 874-7	2.3	4
106	Comparative effectiveness of antihypertensive therapeutic classes and treatment strategies in the initiation of therapy in primary care patients: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. 2013 , 26, 529-38		33
105	Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. <i>Journal of Hypertension</i> , 2013 , 31, 1245-55	1.9	10
104	A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. 2013 , 9, 521-8		3
103	Current perspectives on combination therapy in the management of hypertension. 2013 , 6, 69-78		19
102	The TRINITY Study: distribution of systolic blood pressure reductions. 2013 , 6, 89-99		1
101	Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. 2013 , 6, 101-9		16
100	Patient Demographics and Drug Prescription Pattern among Hypertensive Patients of Pokhara Valley. 2013 , 3, 32-35		3
99	Adherence and health care costs with single-pill fixed-dose combinations in hypertension management. 2014 , 20, 93-100		8
98	An overview of fixed-dose combinations of antihypertensive drugs in South Africa. 2014 , 56, 206-211		2
97	Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. <i>Journal of Hypertension</i> , 2014 , 32, 2054-63; discussiom 2063	1.9	34
96	Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control. 2014 , 68, 163-72		1
95	Delapril and manidipine characterization and purity evaluation in raw materials. 2014 , 115, 2295-2301		4
94	Drug treatment of hypertension in pregnancy. 2014 , 74, 283-96		57
93	Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. 2014 , 37, 154-62		5

92	Changes in blood pressure classification, blood pressure goals and pharmacological treatment of essential hypertension in medical guidelines from 2003 to 2013. 2014 , 2, 1-10		2
91	Review of blood pressure control rates and outcomes. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 127-41		47
90	Recent clinical trials. Journal of the American Society of Hypertension, 2014, 8, 770-4; quiz 775-6		
89	Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 743-57		38
88	Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. 2014 , 15, 605-21		39
87	Searching for synergy in silico, in vitro and in vivo. 2014 , 1, 30-43		22
86	Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. 2014 , 121, 1210-8; discussion 1220		61
85	The evolving clinical management of hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 917-24	2.3	5
84	Identification and evaluation of risk factors in patients with continuously uncontrolled hypertension. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 281-9	2.3	5
83	MicroRNA Profiling Response to Acupuncture Therapy in Spontaneously Hypertensive Rats. 2015 , 2015, 204367		14
82	Efficacy and safety of perindopril arginine + amlodipine in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 266-74		9
81	Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. 2015 , 38, 132-6		15
80	Arterial hypertension in diabetes: etiology and treatment. 2015 , 1079-1090		1
79	Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. 2015 , 31, 875-81		7
78	Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. <i>Cardiology and Therapy</i> , 2015 , 4, 179-90	2.8	12
77	Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs. 2015 , 31, 2287-96		20
76	Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial. 2015 , 38, 89-96		15
75	Determination of five antiarrhythmic drugs in human plasma by dispersive liquid-liquid microextraction and high-performance liquid chromatography. 2015 , 134, 681-689		53

(2017-2015)

74	Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. 2015 , 37, 260-6		4
73	Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia. 2016 , 16, 122		7
72	Update in Hypertension Therapy. 2016 , 100, 665-93		6
71	American Society of Hypertension Scientific Statements Addressing Resistant Hypertension. Journal of Clinical Hypertension, 2016 , 18, 175-8	2.3	2
70	Case study of patents related to captopril, Squibb@ first blockbuster. 2016 , 26, 1449-1457		3
69	Rationale and strategies for formulation development of oral fixed dose combination drug products. 2016 , 46, 615-631		14
68	The 10(th) Annual Cardiometabolic Health Congress General Session Highlights. 2016 , 128 Suppl 1, 1-10)	1
67	Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 mg or Perindopril tert-Butylamine 4 mg Monotherapy. 2016 , 134, 1-10		2
66	The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study. 2016 , 36, 357-66		1
65	Three-way analysis of the UPLC-PDA dataset for the multicomponent quantitation of hydrochlorothiazide and olmesartan medoxomil in tablets by parallel factor analysis and three-way partial least squares. 2016 , 148, 144-52		11
64	Clinical Treatment of Vascular Diseases. 2017 , 233-251		
63	A Fixed-Dose Combination of Bisoprolol and Amlodipine for Hypertension: A Potential Benefit to Selected Patients. <i>Clinical Pharmacology in Drug Development</i> , 2017 , 6, 6-8	2.3	2
62	A quarter-dose quadpill for initial treatment of hypertension. Lancet, The, 2017, 389, 989-990	40	1
61	Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats. Naunyn-Schmiedebergm Archives of Pharmacology, 2017, 390, 457-470	3.4	1
60	Macro-Raman spectroscopy for bulk composition and homogeneity analysis of multi-component pharmaceutical powders. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 141, 180-191	3.5	28
59	Effect of guest drug character encapsulated in the cavity and intermolecular spaces of Exyclodextrins on the dissolution property of ternary Exyclodextrin complex. <i>International Journal of Pharmaceutics</i> , 2017 , 531, 543-549	6.5	8
58	Simultaneous voltammetric determination of antihypertensive drugs nifedipine and atenolol utilizing MgO nanoplatelet modified screen-printed electrodes in pharmaceuticals and human fluids. <i>Sensors and Actuators B: Chemical</i> , 2017 , 252, 1045-1054	8.5	48
57	Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data. <i>Journal of Hypertension</i> , 2017 , 35, 1758-1767	1.9	12

56	National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. <i>American Heart Journal</i> , 2017 , 186, 29-39	4.9	7
55	Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives. <i>Steroids</i> , 2017 , 118, 76-92	2.8	15
54	Vascular Diseases for the Non-Specialist. 2017 ,		3
53	Blockers and Diltiazem Combination-Bear in Mind the Risk of Heart Block. <i>JAMA Internal Medicine</i> , 2017 , 177, 1543-1544	11.5	2
52	Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect. <i>Journal of Controlled Release</i> , 2017 , 262, 296-304	11.7	5
51	Chemiluminescence selectivity enhancement in the on-chip Ru(bpy) system: The potential role of buffer type and pH in the determination of hydrochlorothiazide in combined formulations and human plasma. <i>Luminescence</i> , 2017 , 32, 1494-1503	2.5	2
50	Poly (amidoamine) dendrimer-mediated hybrid formulation for combination therapy of ramipril and hydrochlorothiazide. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 96, 84-92	5.1	21
49	Clinical Utility of Amlodipine/Valsartan Fixed-Dose Combination in the Management of Hypertension in Chinese Patients. <i>Cardiovascular Innovations and Applications</i> , 2017 , 2, 265-271	0.1	
48	Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 143-149	2.3	5
47	Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	5
46	Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 165-170	3.8	10
45	TRIPLE ANTIHYPERTENSIVE THERAPY: FOCUS ON EFFICACY AND PROGNOSIS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 458-468	0.5	
44	Photocurable Bioinks for the 3D Pharming of Combination Therapies. <i>Polymers</i> , 2018 , 10,	4.5	9
43	Insights on Eblockers for the treatment of hypertension: A survey of health care practitioners. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1464-1472	2.3	4
42	Chronotherapy for Hypertension. Current Hypertension Reports, 2018, 20, 97	4.7	59
41	Perindopril 3.5 mg/amlodipine 2.5 mg versus renin-angiotensin system inhibitor monotherapy as first-line treatment in hypertension: a combined analysis. <i>Journal of Hypertension</i> , 2018 , 36, 1915-1920	1.9	3
40	Risk of Hospitalization for Cardiovascular Events with Eblockers in Hypertensive Patients: A Retrospective Cohort Study. <i>Cardiology and Therapy</i> , 2018 , 7, 173-183	2.8	4
39	In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 4687-4692	3.4	4

(2012-2018)

38	Association Trends Between Antihypertensive Drug Therapies and Diastolic Hypotension in Emirati Patients with Type 2 Diabetes: A Single-Center Retrospective Longitudinal Study. <i>Diabetes Therapy</i> , 2018 , 9, 1853-1868	3.6	
37	Polyamidoamine Dendrimers for Enhanced Solubility of Small Molecules and Other Desirable Properties for Site Specific Delivery: Insights from Experimental and Computational Studies. <i>Molecules</i> , 2018 , 23,	4.8	28
36	Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. <i>Lancet, The</i> , 2019 , 394, 639-651	40	156
35	3D Printing of a Multi-Layered Polypill Containing Six Drugs Using a Novel Stereolithographic Method. <i>Pharmaceutics</i> , 2019 , 11,	6.4	127
34	Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. <i>Journal of Managed Care & Decialty Pharmacy</i> , 2019 , 25, 678-686	1.9	8
33	Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet. <i>Annals of Pharmacotherapy</i> , 2019 , 53, 402-412	2.9	1
32	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020 , 97, 42-61	9.9	106
31	Counter-regulatory renin-angiotensin system in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 116-129	14.8	198
30	Antihypertensive constituents in Sanoshashinto. <i>Journal of Natural Medicines</i> , 2020 , 74, 421-433	3.3	6
29	Antihypertensive polytherapy in Australia: prevalence of inappropriate combinations, 2013-2018. Journal of Hypertension, 2020 , 38, 1586-1592	1.9	O
28	Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 829-836	2.2	2
27	Blood pressure lowering efficacy of drugs inhibiting the renin-angiotensin system as second-line therapy for primary hypertension. <i>The Cochrane Library</i> , 2020 ,	5.2	
26	Bipolar disorders, obesity, and metabolic disturbances: Mechanisms and implications. 2021 , 257-274		
25	Synthesis, 3D-pharmacophore modelling and 2D-QSAR study of new pyridine-3-carbonitriles as vasorelaxant active agents. <i>New Journal of Chemistry</i> , 2021 , 45, 7731-7740	3.6	1
24	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. <i>Lancet, The,</i> 2021 , 398, 957-980	40	154
23	3D Printing of Thermo-Sensitive Drugs. <i>Pharmaceutics</i> , 2021 , 13,	6.4	7
22	Combination therapy. 2021 , 1-46		
21	Combination Therapy in Hypertension Treatment. 2012 , 59-72		1

20	The effect of acupuncture on high blood pressure of patients using antihypertensive drugs. <i>Acupuncture and Electro-Therapeutics Research</i> , 2013 , 38, 1-15	0.2	17
19	Short Term Safety and Tolerability of a Fixed Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015 , 9, OC10-3	О	6
18	Efficacy and tolerability of «step down» antihypertensive therapeutic approach using Telmisartan in hypertensive patients with metabolic syndrome. <i>Arterial Hypertension (Russian Federation)</i> , 2011 , 17, 425-431	0.7	
17	Mnenie ekspertov Rossiyskogo meditsinskogo obshchestva po arterial@oy gipertonii: znachenie fiksirovannykh kombinatsiy v uluchshenii kontrolya arterial@ogo davleniya. <i>Systemic Hypertension</i> , 2013 , 10, 83-84	1.6	
16	Hypertension and Pregnancy. 2014 , 433-442		
15	I brazilian position paper on antihypertensive drug combination. <i>Arquivos Brasileiros De Cardiologia</i> , 2014 , 102, 203-10	1.2	5
14	Predicting Non-Adherence To Medication Regimen Among Patients With Hypertension: Taking Steps Toward Ecological Approach. <i>Health Sciences</i> , 2015 , 25, 73-79	О	
13	Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. <i>American Journal of Hypertension</i> , 2021 , 34, 531-539	2.3	
12	A Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazide. 2012 , 6, 79-83		
11	Combination therapy in hypertension: new recommendations. <i>Cardiovascular Journal of Africa</i> , 2010 , 21, 120	0.7	1
10	How Hypertension Guidelines Address Social Determinants of Health: A Systematic Scoping Review. <i>Medical Care</i> , 2021 , 59, 1122-1129	3.1	2
9	Efficacy of Single-Pill, Triple Antihypertensive Therapy in Patients with Uncontrolled Hypertension: A Systematic Review and Meta-analysis <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022 , 1	2.9	O
8	Advanced Sensing Performance towards Simultaneous Determination of Binary Mixture of Antihypertensives Using PANICerium Oxide Nanoparticles as Modifier in Carbon Paste Incorporating Graphite and Silicon-Oil. <i>Journal of the Electrochemical Society</i> , 2022 , 169, 066511	3.9	О
7	Customized 3D printed multi-drug systems: an effective and efficient approach to polypharmacy. 2022 , 19, 1149-1163		O
6	Development, Validation and Application of a Novel UHPLC-UV Method for the Simultaneous Determination of Valsartan and Nifedipine in the New Formulation of Self-Nanoemulsifying Drug Delivery Systems. 2022 , 9, 325		0
5	⊞⊞⊞ Ш 2022 , 15, 4-7		О
4	Mathematical modeling of antihypertensive therapy. 13,		О
3	Risk Factors Control After an Acute Coronary Syndrome and Association with Major Adverse Cardiovascular Events: A Single Center Experience in Latin-America. 2023 , 30, 183-189		O

2 Management of Cardiovascular Risk Factors in Type 2 Diabetes Mellitus Patients. 89-97

О

Hypertension medication from guidelines to practice: A cohort study in western Iran.

О